In the realm of pharmaceutical innovation, the availability of high-quality chemical building blocks is essential. Bucillamine, identified by its CAS number 65002-17-7, is a prime example of such a crucial intermediate. This sulfur-containing amino acid derivative has garnered attention for its potent immunomodulatory and antirheumatic properties, making it a significant compound in drug development, particularly for conditions like rheumatoid arthritis.

Bucillamine presents as a white to off-white powder, with a molecular formula of C7H13NO3S2 and a molecular weight of 223.31. Its chemical characteristics, including a melting point of 119-123°C, are critical for researchers and formulators. For those seeking to buy Bucillamine, understanding these specifications ensures suitability for various pharmaceutical applications. The demand for high-purity Bucillamine underscores the importance of reliable sourcing channels.

As a well-established antirheumatic agent, Bucillamine's mechanism of action involves inhibiting collagenase activity and positively impacting cellular redox states. This makes it an attractive candidate for further research and development in the pharmaceutical sector. Procurement specialists frequently look for competitive Bucillamine prices from trusted Bucillamine suppliers, often leading them to explore options from China, a global hub for chemical manufacturing.

When planning for Bucillamine bulk purchase, it is imperative to partner with a reputable manufacturer of Bucillamine. This partnership ensures not only the consistent quality and purity of the product but also the reliability of the supply chain. Such reliability is crucial for uninterrupted production cycles and timely delivery of finished pharmaceutical products. The ease with which one can purchase Bucillamine often depends on the supplier's efficiency and commitment to customer service.

Ultimately, Bucillamine (CAS 65002-17-7) is more than just a chemical intermediate; it is a gateway to developing innovative treatments for debilitating diseases. By focusing on quality, competitive pricing, and supply chain integrity, pharmaceutical companies can effectively leverage Bucillamine to advance their product pipelines and contribute to better patient outcomes.